Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry
Disease severity and patient access to AST are major factors driving AST initiation. However, some patients are undertreated. This analysis supports AD patient advocacy for those inadequately managed with conventional therapies. Further investigations are necessary to delineate AST initiation barriers and relevant outcomes.
Authors
- Michael A. Haft
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- Jerry Bagel (ORCID: https://orcid.org/0000-0001-5241-0915)
- Dawn Z. Eichenfield (ORCID: https://orcid.org/0000-0002-1511-3804)
- Keith Knapp (ORCID: https://orcid.org/0000-0002-5469-7363)
- Jamie L W Rhoads (ORCID: https://orcid.org/0000-0002-2859-4168)
- Amy S. Paller (ORCID: https://orcid.org/0000-0001-6187-6549)
- Shannon Schneider
- Julie M. Crawford
- Yestle Kim
- Lawrence F. Eichenfield (ORCID: https://orcid.org/0000-0002-2760-0474)
- Ami Claxton
- Sanjeev Balu
- Breda Muñoz
Institutions
- Northwestern University (US)
- Target (United States) (US)
- University of San Diego (US)
- George Washington University (US)
- Leo Pharma (Australia) (AU)
- University of Utah (US)
- University of California San Diego (US)
- Windsor Dermatology (US)
- Leo Pharma (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1080/03007995.2024.2427883
- Citations
- 2
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.07